Zhifei Biological Products

Update in progress

300122.SZ (Shenzhen)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Chongqing Zhifei Biological Products Co., Ltd. develops, manufactures, markets, distributes, imports, and exports vaccines in China. Its product line includes Recombinant Novel Coronavirus Vaccine (CHO cells); Recombinant Mycobacterium tuberculosis Fusion Protein (Ekear); Haemophilus influenzae type b vaccine (XiFeiBei); ACYW135 meningococcal polysaccharide vaccine (Menwayc); Mycobacterium vaccae for injection (Vaccae); meningococcal Groups A and C polysaccharide conjugate vaccine (Mening A Con); and other products. The company also offers cold storage services and was founded in 2002, based in Chongqing.

Company score

Sentiment: 0.46; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.14; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketShenzhen (SHZ)
LocationChina
Founded2002
Employees6,292
Websitewww.zhifeishengwu.com

Identifiers

ISINCNE100000V20